JP2002522386A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002522386A5 JP2002522386A5 JP2000563276A JP2000563276A JP2002522386A5 JP 2002522386 A5 JP2002522386 A5 JP 2002522386A5 JP 2000563276 A JP2000563276 A JP 2000563276A JP 2000563276 A JP2000563276 A JP 2000563276A JP 2002522386 A5 JP2002522386 A5 JP 2002522386A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrogen
- indole
- ethyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- -1 indole compound Chemical class 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 5
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 5
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 5
- 230000002452 interceptive effect Effects 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012453 solvate Chemical class 0.000 description 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 1
- OMJKVIFSWSQTGQ-UHFFFAOYSA-N 6,7-bis(aziridin-1-yl)quinazoline-5,8-dione Chemical compound C1CN1C=1C(=O)C2=NC=NC=C2C(=O)C=1N1CC1 OMJKVIFSWSQTGQ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9510998P | 1998-08-03 | 1998-08-03 | |
| US60/095,109 | 1998-08-03 | ||
| PCT/US1999/017460 WO2000007591A1 (en) | 1998-08-03 | 1999-08-02 | INDOLE sPLA2 INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002522386A JP2002522386A (ja) | 2002-07-23 |
| JP2002522386A5 true JP2002522386A5 (enExample) | 2006-07-27 |
Family
ID=22249729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000563276A Withdrawn JP2002522386A (ja) | 1998-08-03 | 1999-08-02 | インドールｓＰＬＡ２インヒビター |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6608099B1 (enExample) |
| EP (1) | EP1100493A4 (enExample) |
| JP (1) | JP2002522386A (enExample) |
| AU (1) | AU5331499A (enExample) |
| CA (1) | CA2338727A1 (enExample) |
| WO (1) | WO2000007591A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1100493A4 (en) * | 1998-08-03 | 2001-10-24 | Lilly Co Eli | SPLA 2 INHIBITORS? OF THE INDOLTYPS |
| WO2001055108A2 (en) * | 2000-01-25 | 2001-08-02 | Eli Lilly And Company | Use of spl a2 inhibitors for the treatment of inflammation |
| AU2001232734A1 (en) * | 2000-03-09 | 2001-09-17 | Eli Lilly And Company | Compositions containing potential spla2 inhibitors for the treatment of pain |
| EP1303262A2 (en) * | 2000-07-14 | 2003-04-23 | Eli Lilly And Company | Use of a spla2 inhibitor for the treatment of sepsis |
| DE60208065T2 (de) | 2001-08-09 | 2006-07-13 | Eli Lilly And Co., Indianapolis | Cyclohept'b! indolderivate als spla2-inhibitoren |
| US7160909B2 (en) | 2001-08-09 | 2007-01-09 | Eli Lilly And Company | Cyclopenta[b]indole derivatives as sPLA2 inhibitors |
| AUPS282602A0 (en) | 2002-06-07 | 2002-06-27 | Garvan Institute Of Medical Research | Method of inhibiting cell proliferation |
| EP1479677A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
| WO2005107767A2 (en) * | 2004-05-03 | 2005-11-17 | Ilypsa, Inc. | Modulation of lysophosphatidylcholine and treatment of diet-induced conditions |
| WO2007056279A2 (en) * | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors |
| AU2006311851A1 (en) * | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Azaindole compounds and use thereof as phospholipase-A2 inhibitors |
| JP2009517341A (ja) * | 2005-11-03 | 2009-04-30 | イリプサ， インコーポレイテッド | Ｃ４−アミド置換基を有するインドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用 |
| WO2007056280A1 (en) * | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors |
| WO2007056281A2 (en) | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors |
| EP4008327A1 (en) | 2009-04-29 | 2022-06-08 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL109309A (en) | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| IL109311A0 (en) | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
| ATE220394T1 (de) | 1994-04-01 | 2002-07-15 | Lilly Co Eli | 1h-indol-3-glyoxylamid spla2 inhibitoren |
| US5641800A (en) * | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
| CA2338855A1 (en) * | 1998-08-03 | 2000-02-17 | Eli Lilly And Company | Indole spla2 inhibitors |
| EP1100493A4 (en) * | 1998-08-03 | 2001-10-24 | Lilly Co Eli | SPLA 2 INHIBITORS? OF THE INDOLTYPS |
-
1999
- 1999-08-02 EP EP99938937A patent/EP1100493A4/en not_active Withdrawn
- 1999-08-02 AU AU53314/99A patent/AU5331499A/en not_active Abandoned
- 1999-08-02 WO PCT/US1999/017460 patent/WO2000007591A1/en not_active Ceased
- 1999-08-02 CA CA002338727A patent/CA2338727A1/en not_active Abandoned
- 1999-08-02 US US09/762,070 patent/US6608099B1/en not_active Expired - Fee Related
- 1999-08-02 JP JP2000563276A patent/JP2002522386A/ja not_active Withdrawn
-
2003
- 2003-03-21 US US10/395,657 patent/US7026348B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002522386A5 (enExample) | ||
| JP2002502874A5 (enExample) | ||
| JP2002508362A5 (ja) | １−置換−１−アミノメチル−シクロアルカン誘導体（＝ガバペンチン類縁体） | |
| JP2003519676A5 (enExample) | ||
| WO2001087845A3 (en) | N-containing heterocyclic compounds and their use as 5-ht antagonists | |
| JP5702392B2 (ja) | キサンチンオキシダーゼ阻害剤として効果的な新規化合物、その製造方法及びそれを含有する医薬組成物 | |
| JP2002508352A5 (ja) | ４(３)置換−４(３)−アミノメチル−（チオ）ピラン又はピペリジン誘導体（＝ガバペンチン類似体） | |
| JP2004500347A5 (enExample) | ||
| JP2002534523A5 (enExample) | ||
| JP2002522385A5 (enExample) | ||
| KR950701622A (ko) | 안기오텐신 ii 리셉터 안타고니스트 특성을 지니는 치환된 1,2,3,4-테트라하이드로 이소퀴놀린(substituted 1,2,3,4-tetrahydroisoquinolines with angiotensin ⅱ receptor antagonist properties) | |
| JP2005510476A5 (enExample) | ||
| JP2007508359A5 (enExample) | ||
| JP2001519410A5 (enExample) | ||
| LU92113I2 (fr) | Perampanel et ses dérivés pharmaceutiquement acceptables (FYCOMPA) | |
| JP2002543183A5 (enExample) | ||
| CA2401502A1 (en) | Carboxylic acid derivatives as ip antagonists | |
| JP2012505234A5 (enExample) | ||
| KR920021516A (ko) | 기관지 확장제 및 소염제로서의 페닐 피라졸리디논 | |
| EA200000731A1 (ru) | Альфа-аминоамидные производные, полезные в качестве анальгетических агентов | |
| WO2001009103A3 (en) | Imidazole antiproliferative agents | |
| JP2005519916A5 (enExample) | ||
| JP2002529532A5 (enExample) | ||
| JP2004501940A5 (enExample) | ||
| JP2007534702A5 (enExample) |